Remix Therapeutics announced earlier this summer plans to go public via a reverse merger - it's on the back of clinical data that was presented for its RNA modulator at ASCO
Co-Founder and CEO Pete Smith describes how Remix uses small molecules to stop the transcription of disease causing mRNAs. The lead program targets MYB and is in a phase 1/2 for adenoid cystic carcinoma. The reverse merger could close towards the end of year.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.